In an interview with CNN This Tuesday (28), the President of the Butantan Institute, Dr. Esper Kallás he said that 2025 will be a difficult year for Brazil due to the increase in dengue cases.
According to Kallás, the accumulation of cases in early January this year recalls the pattern observed in 2024, suggesting that the numbers can be similar or even superior.
“Maybe we have similar numbers, though a little less, but it may just be a delay in the notification,” he warned.
Current dengue situation in Brazil
Dr. Roberto Kalil, also present in the interview, warned about the severity of the current dengue situation in the country.
“This year has a greater concern, as we have dengue type 1, 2 and 3, which is another type of dengue that has not appeared for ten years,” said Kalil, adding that this can lead to more severe forms of the disease, like the dengue hemorrhagic .
With 21 confirmed deaths and more than 46,000 cases only in January 2024 health authorities are on alert.
The Ministry of Health also reports another 90,000 cases under analysis.
Prevention
Given this perspective, the director of Butantan emphasized the need for preparation and implementation of preventive measures.
“We have to prepare, the year will be more difficult, and we have to implement traditional prevention measures,” said Kallás.
He also highlights the importance of continuous surveillance and the adoption of effective dengue -fighting strategies.
While the vaccine is not widely available, experts reinforce the importance of traditional preventive measures, such as eliminate , repellent and seek medical attention At the first sign of symptoms such as high fever, body pain, headache and especially pain behind the eyes.
Dengue vaccine
The Butantan Institute is advancing in the development of a dengue vaccine, expecting Anvisa’s approval between March and April this year.
According to Kallás, the Butantan vaccine is designed to combat the four known dengue types.
“What the vaccine needs to have dengue is the representation of the four types of dengue,” explained the director.
Approval process in progress
The Butantan Institute submitted the necessary documentation to Anvisa on December 16, starting the approval process.
“Anvisa is analyzing, we hope you have an answer with clarification of anything within this package, which is a usual in the process of approving any product for human use here in Brazil, in mid -March, April,” said Kallas .
Despite the advance, the director stressed that the impact of vaccination will not be immediate.
“We will not have a quantity of vaccines, whether from Butantan or another vaccine that the Ministry of Health has already been implementing, because the number of doses is small, to have such a significant impact by 2025,” he explained.
However, he predicts that “in 2026 the opportunity to confront the vaccine is very good within the perspective that the institute is working.”
The texts generated by artificial intelligence in CNN Brazil They are made based on the video cuts of the newspapers of their programming. All information is cleared and checked by journalists. The final text also involves the revision of the journalism team of CNN . Click here to learn more.
This content was originally published in Dengue: “2025 will be a difficult year in Brazil,” says Butantan director to CNN on CNN Brazil.
Source: CNN Brasil
David
David
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
.